Recently published AAP clinical practice guidelines for the evaluation and treatment of children and adolescents with obesity recommend NAFLD screening via serum alanine aminotransferase (ALT) measurement starting at 10 years of age in those with obesity, or overweight when additional risk factors, including signs of insulin resistance, prediabetes or T2D, dyslipidemia, and sleep apnea, are present [9]. This evidence concerns the gene GPT and type 2 diabetes mellitus.